Optimal fosamprenavir regimen to prevent lipid abnormalities.
We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 naive monoinfectd- HIV-seropositive patients. Eighteen months after starting antiretroviral therapy (ART), all patients showed a good immuno-virological response, with no statistically significant differences among the three groups; no changes in ART regimens were necessary and no adverse events were reported. On the contrary, a statistically significant difference among the three groups of patients was observed in cholesterol and triglyceride levels, since higher levels of cholesterol (including LDLs) and triglycerides were observed in patients taking the higher dose of ritonavir. (www.actabiomedica.it)
Lattuada
Emanuela
E
Infectious Disease Unit, G.B. Rossi Hospital, Verona, Italy.
Lanzafame
Massimiliano
M
Grosso
Carmela
C
Soldani
Fabio
F
Corsini
Fabiana
F
Storato
Silvia
S
Vento
Sandro
S
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D002219:Carbamates / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006679:HIV Seropositivity / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010755:Organophosphates / Q000008:administration & dosage*; D019438:Ritonavir / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage*; D014280:Triglycerides / Q000097:blood
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D010755:Organophosphates; D013449:Sulfonamides; D014280:Triglycerides; D019438:Ritonavir; C426859:fosamprenavir